

*Considered  
SPT 7/18/16*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/691,033  
Applicant : Zongqin Xia, et al.  
Filed : October 21, 2003  
Art Unit : 1654  
Examiner : Susan D. Coe  
Title : SMILAGENIN AND ITS USE  
  
Docket No.: HASEL-65949  
Customer No. : 24201

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

I, Daryl Rees, hereby declare as follows:

1. This Declaration supplements the Declaration I have previously provided in this matter.
2. This Declaration relates to the objections raised in the Office Action dated 29 August 2005, which I have reviewed, and the matters discussed at the interview that I attended with Examiner Coe on March 8, 2006.
3. In the Office Action dated 29 August 2005, Examiner Coe argued that, while *in vitro* cell cultures and rat models "may be effective for screening possible anti-Parkinson's candidates, these models are not necessarily predictive of results in human patients".
4. Examiner Coe further argued that:

"the art teaches that effective treatment of Parkinson's disease in rat models does not necessarily predict successful treatment in humans due